Evotec SE (OTCPK:EVOTF) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET

Company Participants

Dr. Werner Lanthaler - Chief Executive Officer

Enno Spillner - Chief Financial Officer

Cord Dohrmann - Chief Scientific Officer

Craig Johnstone - Chief Operating Officer

Matthias Evers - Chief Business Officer

Conference Call Participants

Zoe Karamanoli - RBC Capital Markets

James Quigley - Morgan Stanley

Christian Ehmann - Warburg Research

Steven Mah - Cowen

Derik de Bruin - Bank of America

Falko Friedrichs - Deutsche Bank

Joseph Hedden - Rx Securities

Operator

Good day, ladies and gentlemen. And welcome to the Evotec SE Half Year Report 2022 Conference Call. For information, today’s conference is being recorded.

And at this time, I’d like to turn the call over to your host today, Dr. Werner Lanthaler. Please go ahead, sir.

Dr. Werner Lanthaler

Thank you very much and good morning and a great day to everyone. Accelerating precision medicine, that’s the theme of today’s analyst presentation for our first half of 2022. Welcome to this. We have uploaded a presentation and will guide you through this presentation throughout the next couple of minutes.

If you go to page number two, you can see that I am here together with my team. I am here with our CFO, Enno Spillner; our CSO, Cord Dohrmann; our COO, Craig Johnstone; and we are very happy to give you a brief update about our recent quarters and also an outlook for the remainder of 2022 and into the longer aspirations of Evotec. Our recently joined new colleague, Matthias Evers, is also on the call and we are very happy that he joined us recently.

If you go to page number four of your presentation, you can see that significant new partnerships based on data driven platforms are accelerating our company. We see strong overall performance and progress in all lanes of the so-called R&D Autobahn to Cures. Actually, I think it’s fair to say that we see a very strong business inflow.

We see a very strong business inflow despite a somewhat challenging funding environment for some of our especially biotech colleagues. And we also can already today see a very strong demand into 2023.

So with this, so far, we do not notice any impact for a more compromised funding environment of biotechs. When we look forward, we expect several very important milestones, which allow us to overall confirm our strong business outlook for the rest of 2022.